Japan – Peripheral Artery Disease and Critical Limb Ischemia Prevalence and Incidence 2017
Research on the epidemiology of peripheral artery disease (PAD) and critical limb ischemia (CLI) in Japan is sparse to nonexistent.
The prevalence of diabetes is rapidly increasing worldwide. Diabetes has grown at a faster rate in Asia than in Western countries, reaching epidemic proportions in the region. Over the last several decades, the number of diabetics in Japan has risen significantly, reflecting the combination of growing obesity, decline in physical activity and the aging population.
Employing the Diabetes Method, the 2015 prevalence of PAD and CLI is estimated for Japan, and the prevalence of each is projected for the 2015-2030 period. PAD and CLI incidence estimates are also included for 2015-2030. PAD prevalence in recently published Japanese studies is assessed and compared with THE SAGE GROUP estimates.
The number of symptomatic and asymptomatic Japanese PAD cases is estimated for 2015-2030 with specific estimates for intermittent claudication (IC) and critical limb ischemia. Since only a fraction of IC and CLI patients are diagnosed and treated, the number of CLI and IC patients diagnosed and treated is included. These estimates represent the current actual market for interventional therapies.
Prevalence is defined as the number of new and old cases of PAD and CLI. Incidence is defined as the annual number of new cases of these diseases.
The Diabetes Method is an age- and glucose-based method to estimate atherosclerotic lower limb disease. Employing U.S. Census Bureau’s International Data Base (IDB), the population is segmented into 3 age groups.
Within each of these age groups, the population is divided into two glucose states: Diabetic (diagnosed and undiagnosed) and Nondiabetic (normal glucose and prediabetes). PAD is calculated according to the percentage prevalence in each glucose state. Then the prevalence of CLI is calculated in those with PAD by glucose status.
Price: $3,800
To purchase
Email yost@thesagegroup.us.